Points of discussion
• Definition of NET & NETosis
• Brief history
• Types
• Mechanism of NET formation
• Action of NETs
• NETs and autoimmunity
• Therapy related to NET
• COVID & NETosis
NET – Definition
• NETs are large, extracellular, web-like structures composed of
cytosolic and granule proteins that are assembled on a scaffold
of decondensed chromatin
• Majority of DNA from nucleus , also from mitochondria
• NETs trap, neutralize and kill bacteria, fungi, viruses and
parasites and are thought to prevent bacterial and fungal
dissemination
History
• In 2004 , Brinkmann et al described NET
• Stimulation with IL8, PMA , LPS & visualization with EM and IF
- NETs were observed
• Under EM - NETs were composed of linear elements about 15–17
(nm) in diameter and are studded with globules
• The backbone of these NETs was composed of DNA and histones as
demonstrated by IF
NETOSIS -definition
• NET release occurs primarily through a cell death process
termed NETosis
• 2007 - it is declared as unique cell death pathway of
neutrophil
• During NETosis, neutrophils release NETs, which can capture
and kill bacteria and other pathogens to prevent them from
spreading.
lytic NETosis – suicidal
• Slow cell death
• Neutrophils arrest their actin dynamics and depolarize
• Nuclear envelope disassembles
• Delobulation of nuclei
• Nuclear chromatin decondenses into the cytoplasm mixing with
cytoplasmic and granule components
• Plasma membrane then permeabilizes
• NETs expand into the extracellular space 3–8 hours after neutrophil
activation
Non-lytic NETosis – vital
• It leads to the rapid release of NETs within minutes of
exposure to Staphylococcus aureus via the secretion of
chromatin and granule contents
• No cell death – rapid response
• Seen in small fraction of neutrophils during systemic
S. aureus infection
• Generates NETs and anucleated cytoplasts that crawl and
phagocytose bacteria
Basic steps
1. Activation of ROS by NOX or NOX independent pathway
2. Release of NE and translocation to nucleus
3. MPO- NE mediated chromatin decondensation
4. Hyper-citrullination of chromatin
5. Nuclear and cell membrane permeabilization
6. Release of NET
ROS activation
• ROS generated by NADPH oxidase stimulate MPO to trigger the
activation and translocation of NE to the nucleus
• ROS-inducing receptors & kinases - MEK (MAPK/ERK kinase),
ERK, IRAK, PKC, PI3K and AKT – activate ROS in response to
PMA, microorganisms, parasites and immobilized immune
complexes
• Requirement for PI3K in NETosis has also implicated a role for
autophagy
MPO- NE pathway
• NE binds to F-actin filaments in the cytoplasm and degrade
them & enter the nucleus
• NE proteolytically processes histones to disrupt chromatin
packaging
• MPO binds chromatin and synergizes with NE in
decondensing chromatin independently of its enzymatic
activity
• MPO–NE pathway is induced by many NET stimuli, such as
fungi and crystals
Other biochemical events
• In resting neutrophils - fraction of MPO is bound to NE as
part of a complex called the azurosome
• H2O2 - selectively releases NE into the cytosol in an MPO-
dependent manner at physiological condition
• Chlorinated polyamines - crosslink NET proteins, increasing
NET stability and integrity and potentiating the capture of
microorganisms
NOX – independent pathway
• Immune complexes, ionomycin and nicotine, trigger NETosis
independently of NOX , relying instead on mitochondrial
ROS
• Non-lytic NETosis is also thought to occur independently of
ROS
• Glycans in saliva induce NETs via an unknown mechanism
Chromatin decondensation
• Histone deamination or hyper citrullination
• Driven by peptidylarginine deiminase 4 (PAD4)
• H202 - is sufficient to activate PAD4 which requires calcium
and is activated by PKC
• PAD4 inhibition blocks NET release in mouse models of
sepsis and cancer
• Histone citrullination and MPO-NE activity lead to
chromatin decondensation
Membrane permeabilization
• Plasma membrane permeabilization occurs in a programmed
manner & not as a consequence of physical disruption by the
expanding chromatin
• Monosodium urate (MSU) crystals promote necroptosis with
receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
and RIPK3,
Regulation of NETosis
• Larger microorganisms- NET
• Larger particle size -NET
• Small virulent microorganisms that interfere with phagosomal
killing
• Large aggregates or abscess – favors NET
• Microbial interference with phagosome maturation ( N .
gonorrhea )
• Presence of motile flagella ( pseudomonas )
• Expression of enzyme ( invasin in yersinia )
• Lacking phagocyte promoting protease – cause NET
Microbiocidal action
• Kill or suppress bacterial ,fungal, viral proliferation
• Underlying mechanisms poorly understood.
• Histones, defensins & cathelicidins - potent antimicrobials
in NETs
• NETosis is also likely to be the major route for the release of
calprotectin
• Physical sequestration of microorganisms by NETs is also
thought to prevent systemic dissemination
NETs promote vaso-occlusion
• Provide a scaffold that promotes DVT
• Hypoxia-induced release of VWF & P-selectin from the endothelium
initiate NET formation
• Thromboxane A2 induces endothelial cell expression of ICAM1 to
strengthen neutrophil interactions
• Platelet- derived high mobility group protein B1 (HMGB1), ROS
and integrins trigger NETosis
Vaso-occlusion
• NETs recruit Factor XIIa
• Mobilizes endothelial cell granules (Weibel–Palade bodies)
that contain VWF, P-selectin , Factor XIIa
• Extracellular NET histones bind VWF and fibrin to recruit
platelets and red blood cells
• NET-bound NE cleaves tissue factor pathway inhibitor (TFPI)
and proteolytically activates platelet receptors to increase
platelet accumulation
Other vascular events
• NETs form in response to the build-up of bicarbonate salts and
occlude pancreatic ducts to drive pancreatitis
• NETosis in response to free haem may contribute to vaso-
occlusion in sickle cell disease
NETs modulate sterile inflammation
• NETs regulate inflammatory cytokines directly or indirectly by
modulating immune cells
• Early inflammatory stages induce NETs by IL-6 & pro-IL-
1β in macrophages via TLR2 & 4
• Th 17 cell increased
• Increased myeloid cell recruitment to site of inflamed lesions
like atherosclerotic plaque
Sterile inflammation ( contd )
• Mouse model of ischaemia– reperfusion injury - NETs amplify
inflammation and liver damage
• NETs and neutrophil-derived IL-17 – role in Alzheimer
disease
• NETs promote inflammation and tissue destruction - delay
wound healing in diabetes
• Glucose is required for NETosis & neutrophils from patients
with diabetes release NETs more readily
• NETs - detected in adipose tissues of obese mice
Sterile inflammation ( contd )
Anti-inflammatory response
• NETs were suggested to have an anti-inflammatory
role in mouse models of gout induced by MSU
crystals
• It is possible that NETs initiate inflammation and, as
they build up over time, potentiate its resolution.
NETS in autoimmunity
• NETs - source of self-antigen in autoimmune diseases
• Autoantibodies against neutrophil- derived proteins
• NET - first reported in kidney biopsy in ANCA-
associated vasculitis - antibodies against NET
components , MPO & proteinase 3
• Nuclear material released from NETs more immunogenic
• Oxidised DNA in NET – promote IFN 1 signalling
SLE
• NETs activate plasmacytoid dendritic cells (pDCs) via TLR9 and
TLR7 signalling & promote type I IFN expression
• Mitochondrial ROS oxidize NET DNA to increase its ability to
activate the stimulator of interferon genes (STING) pathway and
trigger IFN production by pDCs
• small population of circulating low-density granulocytes (LDGs)
releases NETs spontaneously
Rheumatoid arthritis
• Enhanced NETosis - detected in circulating & synovial-fluid
neutrophils, synovial tissue, rheumatoid nodules, skin of
affected patients
• NETs are a source of extracellular citrullinated autoantigens
• Release of active PAD isoforms through NETosis, citrullinate
extracellular histones and fibrinogen in RA
• It stimulate production of proinflammatory cytokines,
chemokines & adhesion molecules in synovial fibroblasts
ANCA associated vasculitis
• Antibodies to MPO & PR3 – pathogenic
• They activate neutrophils primed by a proinflammatory stimuli,
leading to respiratory burst
• Enhanced NET formation in vitro
• Lvels of NET remnants (MPO–DNA complexes), and
neutrophil granular proteins, such as calprotectin , were
increased in sera of AAV
• NET formation is involved in vascular damage and immune
system activation in AAV
AAV – NET
• ANCA induced NETs generated by C5a-primed neutrophils cause
enhanced thrombosis & inflammation in AAV by promoting the
expression of tissue factor
• NETs can also present PR3 and MPO to dendritic cells
• NETs - important sources of modified autoantigens in the kidney.
• In necrotizing crescentic glomerulonephritis, neutrophil serine
proteases like cathepsin G, neutrophil elastase and PR3 promoted
IL-1β generation and kidney injury
APS
• NETs - important activators of the coagulation cascade &
integral components of arterial and venous thrombin
• Serum of APS displays - decreased ability to degrade NETs
• Elevated levels of both cell-free DNA and NET remnants
• aPLs promote the release of NETs in a ROS and TLR4-
dependent manner
• A LDG population has also been described in primary AP
Therapeutic strategy in autoimmunity
• Inhibition of ROS production by targeting NADPH or
mitochondria
• ROS scavenger - N-acetyl cysteine (NAC) reduce NET release
• MPO inhibitors - 4-aminobenzoic acid hydrazide or PF-1355-
reduce NETosis, neutrophil recruitment and levels of circulating
cytokines
• TLR inhibitor - TAK-242
• PAD inhibitors - Cl-amidine , BB-Cl-amidine
• Targeting B cells & plasma cells - reduction of autoantibody-
induced NET formation
• Inhibitors of calcineurin or GPCR phospholipase C
( staurosporine ) - suppress or modulate NETosis
• DNase 1 - enhance their clearance
• Targeting CXCL5 - decrease TH17-mediated autoimmunity -
crescentic glomerulonephritis
• Inhibition of TNF and IL-17 decreases NET in RA
• Anti-C5 mAb therapy
Therapeutic strategy
A Role for NETosis in COVID-19 Infection?
• Cytokine storm seen with COVID-19 elaborates role of NET
• NETs can induce macrophages to secrete IL1β & form a loop
between macrophages and neutrophils, leading to progressive
inflammatory damage.
• Virus -induced NETs can circulate in an uncontrolled way, leading
to an extreme systemic response of the body like ARDS .
• NETs can be detected in tissues by immunohistochemistry & in
blood by sandwich ELISA
NET – lung damage – therapeutic
aspect in COVID 19
Take home message
1. NETosis- programmed cell death , unique in neutrophil
2. NETs are extracellular web like structure on scaffold of decondensed
chromatin with granules
3. Either suicidal causing cell death or vital where no lysis happens
4. Mecahnism - activation of ROS , MPO-NE pathway , chromatin
decondensation and increased permeability
5. It has multiple actions – microbiocidal , damage host tissue , sterile
inflammation ( atherosclerosis , diabetes ),vaso –occlusion(DVT) and
autoimmunity, malignancy
6. SLE , AAV ,gout ,RA , cresecentic GN – NET has important role
7. Therapeutic target of NETs are emerging
8. COVID 19 – NET – association is highly possible
References
1. Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease.
Nat Rev Immunol 18, 134–147 (2018)
2. Gupta, S., Kaplan, M. The role of neutrophils and NETosis in autoimmune
and renal diseases. Nat Rev Nephrol 12, 402–413 (2016).
3. De Bont, C.M., Boelens, W.C. & Pruijn, G.J.M. NETosis, complement, and
coagulation: a triangular relationship. Cell Mol Immunol 16, 19–27 (2019).
4. Miguel Antonio Mesa1 and Gloria Vasque . NETosis . Autoimmune Diseases
/ 2013
5. Elsherif L, Sciaky N, Metts CA, et al. Machine Learning to Quantitate
Neutrophil NETosis. Sci Rep. 2019;9(1):16891.
6.. Bryan G. Yipp, Paul Kubes; NETosis: how vital is it?. Blood 2013; 122
(16): 2784–2794
7. Boilard,E., Fortin, P. Mitochondria drive NETosis and inflammation in
SLE. Nat Rev Rheumatol 12, 195–196 (2016
8. Xavier Bosch. Systemic Lupus Erythematosus and the Neutrophil. N Engl
J Med 2011; 365:758-760
9. Nicoletta Sorvillo. Circulation Research. Extracellular DNA NET-Works
With Dire Consequences for Health, Volume: 125, Issue: 4,
References